Keyphrases
Biliary Tract Cancer
100%
Cholangiocarcinoma
60%
Prognostic Biomarker
48%
Intrahepatic Cholangiocarcinoma (iCCA)
40%
Overall Survival
27%
Tumor
25%
Interleukin-6
23%
YKL-40
23%
Carbohydrate Antigen 19-9 (CA19-9)
23%
Blood-based
20%
Tumor Immunotherapy
20%
Present Challenges
20%
Treatment Refractory
20%
Desmoplastic Tumor
20%
Tumor Fibrosis
20%
Rapid Progressors
20%
Chemotherapy
20%
Metastatic Colorectal Cancer (mCRC)
20%
Whole Blood
20%
Interleukin-6 Receptor (IL-6R)
20%
Diagnostic Potential
20%
Molecular Current
20%
Current Therapies
20%
Diagnostic Biomarker
20%
Blood microRNA
20%
Tumor-like
20%
Bile Duct Cells
20%
MicroRNA-27a-3p
20%
Molecular Therapeutic Targets
20%
Molecular Portrait
20%
Circulating Proteins
20%
Exome Sequencing
20%
Tumor Microenvironment
20%
Long-term Survivors
20%
FoxO
20%
Molecular Pathogenesis
20%
Fibrosis Marker
20%
Genomic Landscape
20%
Therapeutic Target
20%
Interleukin-15 (IL-15)
20%
Protein Signature
20%
MicroRNA
17%
PRO-C3
16%
Transcriptomic Signature
15%
Gemcitabine
15%
Genetic Modification
15%
Driver mutations
13%
Phase II Trial
13%
PRO-C6
13%
Patient Outcomes
13%
Medicine and Dentistry
Biliary Tract Cancer
100%
Cholangiocarcinoma
80%
Neoplasm
78%
Biological Marker
58%
Diagnosis
48%
Disease
28%
Overall Survival
27%
Malignant Neoplasm
24%
Interleukin 6
23%
CA19-9
23%
microRNA
20%
Interleukin 15
20%
Tumor Microenvironment
20%
Metastatic Colorectal Cancer
20%
Exome Sequencing
20%
Fibrosis
20%
Cancer Immunotherapy
20%
Molecular Pathology
20%
Gemcitabine
18%
Extracellular Matrix
16%
Oncology
12%
Transcriptome
12%
Biliary Duct Cancer
11%
Proportional Hazards Model
10%
Stroma
10%
Targeted Therapy
10%
Epithelioma
10%
Colorectal Cancer
9%
Recurrent Disease
9%
Cancer Types
9%
Cancer
8%
Biopsy
8%
Hazard Ratio
8%
Transcriptomics
8%
Drug Resistance
8%
In Vitro
7%
Carbon 11
6%
Cancer Therapy
6%
Collagen Type 4
6%
Next Generation Sequencing
6%
Collagen Type 3
6%
Metalloproteinase
6%
Genome Sequencing
6%
Experimental Neoplasm
6%
Surgery
6%
Progression Free Survival
6%
RNA Sequence
5%
Oxaliplatin
5%
Cell Communication
5%
Isocitrate Dehydrogenase 1
5%
